Complimentary Biomarker Strategies for More Efficient Early-Phase Drug Development in Alzheimer's Disease

Speakers

John Allinson

VP Biomarker Lab Services, ICON Development Solutions, United Kingdom

Niels Prins, MD, PhD, MSc

CEO, Alzheimer Research Center (ARC), Netherlands

Michael N Liebman, PhD

Managing Director, IPQ Analytics, United States

Michael N. Liebman, Ph.D. is the Manag. Dir. of IPQ Analytics and Strategic Medicine, Exec Dir of Windber Res Inst 2003-2007, Dir., Comp Bio and Biomed Inform. at U of PA Cancer Ctr 2000-2003 and Global Head of Comp Genomics, Roche and Director, Bioinformatics and PGX, Wyeth and co-founded Prosanos

Klaudius Siegfried, PhD

Vice President and Global Leader, Therapeutic Area, Central Nervous System, ICON Clinical Research, Germany